Gut microbiota differences shape metabolic responses to exercise, supporting personalized training, multidisciplinary care, and microbial therapies to improve outcomes for patients with obesity and diabetes.

Metabolomic profiling enables a predictive model for asthma exacerbations, supporting personalized management, reduced hospitalizations, risk stratification, and potential integration of cost-effective biomarkers into routine care.

AI-powered screening shows promise for early Alzheimer’s detection, enabling earlier intervention, better resource allocation, clinician training, and preventive care strategies for at-risk patients nationwide adoption.

Experts warn liver disease absolute risk estimates should exclude time-varying covariates, improving accuracy, guiding clinical decisions, refining guidelines, and supporting patient management and resource allocation.

Distinct chromosomal signatures in uterine leiomyoma subtypes deepen tumor understanding, enabling improved classification, risk stratification, and future personalized diagnostics and therapies for reproductive health care.

Smartphone mental health apps are gaining momentum, offering flexible care options while prompting clinicians to adopt training, hybrid models, and evidence-based integration strategies to meet rising demand.

Studies show patients misunderstand common skin cancer terms, prompting clinicians to simplify communication, strengthen education tools, and improve engagement and adherence across oncology care settings.

Advances in geographic atrophy therapies emphasize slowing progression, leveraging multimodal imaging, refining patient selection, and setting realistic expectations, reshaping how clinicians diagnose, monitor, and manage GA long term.

Persistent gaps in hypertension diagnosis and treatment among adults over 40 highlight urgent needs for better screening, guideline adherence, and targeted interventions to reduce cardiovascular risk.

The theranostic agent 67Cu-SAR-bisPSMA advances in trials, offering a promising, targeted treatment option for metastatic castration-resistant prostate cancer with limited existing therapies.